Posted by Michael Wonder on 20 Aug 2024
Arthrosi Therapeutics receives FDA fast track designation for AR882 in tophaceous gout
19 August 2024 - Arthrosi Therapeutics today announced the US FDA has granted fast track designation to AR882 for the potential treatment of clinically visible tophi in patients with gout.
The Company is currently advancing AR882 in a pivotal Phase 3 program.
